ClinicalTrials.gg
CompletedNCT07282145Updated Sep 29, 2026

Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers

A Phase 1 interventional study of BCD101 Low Dose Liquid Formulation and BCD101 High Dose Liquid Formulation in Essential Hypertension, sponsored by Bichedam Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Bichedam Co., Ltd. · Phase 1, Interventional, and Basic science

How we know

Updated Sep 28, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Essential Hypertension with a site in Korea, Republic of — 11 open to participants now, 13 under way, 4 of them phase 3. Essential Hypertension · Korea, Republic of.

Enrollment
72nd of 86
57 · median 190
Started
2025
with 8 others
Phase 1
21 of 99
none open now
Registered
95th of 99
by date

Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, this one is the 72nd largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2025, is one of 21 in phase 1, and was the 95th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

11 of the 99 studies in Essential Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Essential Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.

The primary objectives of this study are to determine:

  1. The safety and tolerability of BCD101 in healthy adult volunteers.
  2. The pharmacokinetic profile of BCD101 following single and multiple dosing.

A control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.

Key study activities include:

  1. Administration of single and multiple escalating doses of BCD101 and placebo under controlled conditions.
  2. Safety and tolerability assessments, including monitoring for adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and serious adverse drug reactions (SADRs).
  3. Pharmacokinetic (PK) analysis to evaluate the pharmacokinetic characteristics of the investigational product.
03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 years or older at screening.

    • Body weight ≥ 50.0 kg and (BMI) between 18.0 kg/m² and 30.0 kg/m² at screening.

      * BMI (kg/m²) = weight (kg) / {height (m)}²

    • No congenital or chronic medical conditions requiring treatment, and no pathological signs or findings upon medical examination.
    • Clinical laboratory tests, vital signs, physical examination, and 12-lead (ECG) results at screening indicate suitability for participation based on the characteristics of the medicinal product.
    • Fully understood the detailed explanation of this clinical trial, voluntarily agreed to participate, and provided written agreeing to comply with study requirements during the trial period.

Exclusion criteria

  • History or current liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.

    • Female subjects who are pregnant (urine hCG positive) or breastfeeding.
    • History of (e.g., anaphylaxis, angioedema) or clinically significant allergic reactions to the active ingredient, of the product, or other medications (e.g., aspirin, penicillin antibiotics, macrolide antibiotics).
    • History of gastrointestinal diseases or surgeries that could affect absorption of the investigational drug (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis), except simple appendectomy or hernia surgery.
    • Clinically significant abnormalities on 12-lead at screening, including:

      • > 450 ms (males) or > 470 ms (females)
      • PR interval > 200 ms
      • QRS duration > 120 ms
    • Clinically significant laboratory abnormalities at screening, including:

      • Liver function tests (, ALT, ALP, γ-GT, total ) exceeding twice the .
      • Serum creatinine outside the reference range or estimated (eGFR) \< 60 mL/min/1.73m² as calculated by the CKD-EPI formula.
    • History of substance abuse or positive urine drug screening for abuse substances.

Vital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:

  • Systolic blood pressure ≤ 90 mmHg or ≥ 150 mmHg
  • Diastolic blood pressure ≤ 60 mmHg or ≥ 100 mmHg
  • Pulse rate ≤ 40 bpm or ≥ 100 bpm

    • Evidence of orthostatic hypotension at screening.
    • Use of enzyme-inducing or inhibiting drugs such as barbiturates within 1 month prior to first dosing.
    • Abnormal diet or consumption of foods that could affect drug absorption, distribution, metabolism, or excretion.
    • Use of prescription or herbal medications that may affect the investigational product's characteristics within 2 weeks prior to first dosing, or over-the-counter drugs or dietary supplements within 10 days prior to first dosing (except when judged by the investigator not to affect the pharmacokinetics of the investigational product).
    • Participation in another clinical trial with investigational drug administration within 6 months prior to first dosing (the end date of participation is calculated as the day after the last dose of the previous trial).
    • Whole blood donation within 2 months prior to first dosing, donation within 1 month prior to first dosing, blood transfusion within 1 month prior to first dosing, or inability to abstain from blood donation from to PSV.
    • Excessive alcohol consumption (more than 21 units per week; 1 unit = 10 g = 12.5 mL pure alcohol) within 6 months prior to first dosing or inability to abstain from alcohol from informed consent to PSV.
    • Smoking more than 10 cigarettes per day within 3 months prior to first dosing or inability to abstain from smoking from 24 hours prior to first dosing until last blood sampling.
    • Consumption of grapefruit-containing foods within 72 hours prior to first dosing or inability to abstain until PSV.
    • Consumption of caffeine-containing foods or beverages (e.g., coffee, green tea, black tea, carbonated drinks, coffee milk, energy drinks) from 24 hours prior to first dosing until last blood sampling or inability to abstain.
    • Engaging in strenuous exercise exceeding daily activity levels from 48 hours prior to first dosing until PSV or inability to refrain from such exercise.
    • Planning to become pregnant or not using reliable methods (e.g., hormonal contraceptives, intrauterine device, sterilization procedures, barrier methods) for self or partner from informed consent until 90 days after last dose of investigational product.
    • Any other reasons deemed by the investigator to make the subject unsuitable for participation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    SAD-1(Treatment group)

    6 Participants in the SAD-1(Treatment group) arm received a single oral dose of BCD101-1(2 sachets). BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 Low Dose Liquid Formulation

  • Experimental
    SAD-2(Treatment group)

    6 Participants in the SAD-2(Treatment group) arm received a single oral dose of BCD101-2(2 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 High Dose Liquid Formulation

  • Experimental
    SAD-3(Treatment group)

    6 Participants in the SAD-3(Treatment group) arm received a single oral dose of BCD101-2(3 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 High Dose Liquid Formulation

  • Experimental
    SAD-4(Treatment group)

    6 Participants in the SAD-4(Treatment group) arm received a single oral dose of BCD101-2(4 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 High Dose Liquid Formulation

  • Experimental
    MAD-1(Treatment group)

    6 Participants in the MAD-1(Treatment group) arm received BCD101-1(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 Low Dose Liquid Formulation

  • Experimental
    MAD-2(Treatment group)

    6 Participants in the MAD-2(Treatment group) arm received BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 High Dose Liquid Formulation

  • Experimental
    MAD-3(Treatment group)

    6 Participants in the MAD-3(Treatment group) arm received a combination of BCD101-1(1 sachet) and BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet, while BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 Low + High Dose Liquid Formulation

  • Experimental
    SAD-1(Placebo group)

    2 Participants in the SAD-1(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    SAD-2(Placebo group)

    2 Participants in the SAD-2(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    SAD-3(Placebo group)

    2 Participants in the SAD-3(Placebo group) arm received a single oral dose of BCD101-P(3 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    SAD-4(Placebo group)

    2 Participants in the SAD-4(Placebo group) arm received a single oral dose of BCD101-P(4 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    MAD-1(Placebo group)

    2 Participants in the MAD-1(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    MAD-2(Placebo group)

    2 Participants in the MAD-2(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. The study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

  • Experimental
    MAD-3(Placebo group)

    2 Participants in the MAD-3(Placebo group) arm received BCD101-P(2 sachets), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to the active formulations, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

    Drug: BCD101 Placebo Liquid Formulation

Interventions

  • DrugBCD101 Low Dose Liquid Formulation

    \[SAD\] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration. \[MAD\] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.

  • DrugBCD101 High Dose Liquid Formulation

    \[SAD\] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. \[MAD\] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

  • DrugBCD101 Low + High Dose Liquid Formulation

    \[MAD\] A combination of BCD101-1(2 g) and BCD101-2(4 g) liquid formulations, administered orally as separate sachets simultaneously. Used for multiple dosing.

  • DrugBCD101 Placebo Liquid Formulation

    \[SAD Placebo\] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. \[MAD Placebo\] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (Single-Ascending Dose, SAD)

    All adverse events occurring during the clinical trial following a single ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

    Time frame: Day -1, Day 1, post-study visit (Day 4-7)

  2. Physical Examination Abnormalities (SAD)

    A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  3. Vital signs: Systolic and Diastolic Blood Pressure (SAD)

    Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  4. Vital signs: Heart Rate (SAD)

    Heart rate will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  5. Vital signs: Body Temperature (SAD)

    Body temperature will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  6. Electrocardiogram (ECG) Abnormalities (SAD)

    A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  7. Laboratory Abnormalities (SAD)

    Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, post-study visit (Day 4-7)

  8. Number of Participants With Adverse Events (MAD)

    All adverse events occurring during the clinical trial following a multiple ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

    Time frame: Day -1 through Day 7, and post-study visit (Day 8-12)

  9. Physical Examination Abnormalities (MAD)

    A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

  10. Vital signs: Systolic and Diastolic Blood Pressure (MAD)

    Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

  11. Vital signs: Heart Rate (MAD)

    Heart rate will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

  12. Vital signs: Body Temperature (MAD)

    Body temperature will be measured after at least three minutes of rest in the seated position.

    Time frame: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

  13. Electrocardiogram (ECG) Abnormalities (MAD)

    A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

  14. Laboratory Abnormalities (MAD)

    Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

    Time frame: Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)

Secondary outcomes

  1. Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD)

    Cmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose)

  2. Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) (SAD)

    AUC0-t will be calculated using non-compartmental analysis following a single ascending dose of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose)

  3. Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) (SAD)

    AUCinf will be calculated using non-compartmental analysis from the plasma concentration-time profile following a single ascending dose of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose)

  4. Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) (SAD)

    Tmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose)

  5. Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) (SAD)

    Terminal elimination half-life will be estimated from the terminal phase of the plasma concentration-time profile following a single ascending dose of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose)

  6. Pharmacokinetic Parameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)

    Cmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

  7. Pharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD)

    AUCtau,ss will be calculated at steady state during multiple ascending dosing (Day 1-7).

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

  8. Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)

    AUCinf,ss will be calculated using non-compartmental analysis from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

  9. Pharmacokinetic Parameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)

    Tmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

  10. Pharmacokinetic Parameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)

    Terminal elimination half-life at steady state will be estimated from the terminal phase of the plasma concentration-time profile following multiple ascending doses of BCD101.

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

  11. Pharmacokinetic Parameter: Accumulation Ratio (Rac) (MAD)

    Rac will be calculated to assess the accumulation of BCD101 following multiple ascending doses.

    Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, North Chungcheong 28644, South Korea
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 7 months.

Of 18 phase 1 interventional studies under Essential Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 7 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2025 → May 2026 and completion Apr 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 15, 2025
StartActual
Sep 22, 2025
Primary completionActual
May 15, 2026was Sep 2025
CompletionActual
May 15, 2026was Apr 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 28, 2026
Start date
Sep 11, 2025→Sep 22, 2025
Sep 28, 2026
Primary completion
Sep 23, 2025→May 15, 2026
Sep 28, 2026
Study completion
Apr 30, 2026→May 15, 2026 (actual)
Sep 28, 2026
Enrollment
56 (estimated)→57 (actual)
Sep 28, 2026
Primary outcomes
14 description edited
What changed in the outcomes
  • DescriptionElectrocardiogram (ECG) Abnormalities (MAD): how it is measured was reworded
  • DescriptionElectrocardiogram (ECG) Abnormalities (SAD): how it is measured was reworded
  • DescriptionLaboratory Abnormalities (MAD): how it is measured was reworded
  • DescriptionLaboratory Abnormalities (SAD): how it is measured was reworded
  • DescriptionNumber of Participants With Adverse Events (MAD): how it is measured was reworded
  • DescriptionNumber of Participants With Adverse Events (Single-Ascending Dose, SAD): how it is measured was reworded
  • DescriptionPhysical Examination Abnormalities (MAD): how it is measured was reworded
  • DescriptionPhysical Examination Abnormalities (SAD): how it is measured was reworded
  • DescriptionVital signs: Body Temperature (MAD): how it is measured was reworded
  • DescriptionVital signs: Body Temperature (SAD): how it is measured was reworded
  • DescriptionVital signs: Heart Rate (MAD): how it is measured was reworded
  • DescriptionVital signs: Heart Rate (SAD): how it is measured was reworded
  • DescriptionVital signs: Systolic and Diastolic Blood Pressure (MAD): how it is measured was reworded
  • DescriptionVital signs: Systolic and Diastolic Blood Pressure (SAD): how it is measured was reworded
Sep 28, 2026
Secondary outcomes
9 edited, 2 description edited
What changed in the outcomes
  • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC₀AUC0-t) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve ExtrapolatedFrom Time Zero to Infinity (AUCinf) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Time to Maximum Plasma Concentration (Tmax) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Terminal Elimination Half-Life (t1/2) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve ExtrapolatedFrom Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
  • EditedPharmacokinetic ParametersParameter: Accumulation Ratio (Rac) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)
  • DescriptionPharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD): how it is measured was reworded
  • DescriptionPharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD): how it is measured was reworded
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Completed
    Start date Sep 11, 2025→Sep 22, 2025
    Primary completion Sep 23, 2025→May 15, 2026
    Study completion Apr 30, 2026→May 15, 2026 (now actual)
    Enrollment 56 (estimated)→57 (actual)
    Primary outcomes 14 description edited
    What changed in the outcomes
    • DescriptionElectrocardiogram (ECG) Abnormalities (MAD): how it is measured was reworded
    • DescriptionElectrocardiogram (ECG) Abnormalities (SAD): how it is measured was reworded
    • DescriptionLaboratory Abnormalities (MAD): how it is measured was reworded
    • DescriptionLaboratory Abnormalities (SAD): how it is measured was reworded
    • DescriptionNumber of Participants With Adverse Events (MAD): how it is measured was reworded
    • DescriptionNumber of Participants With Adverse Events (Single-Ascending Dose, SAD): how it is measured was reworded
    • DescriptionPhysical Examination Abnormalities (MAD): how it is measured was reworded
    • DescriptionPhysical Examination Abnormalities (SAD): how it is measured was reworded
    • DescriptionVital signs: Body Temperature (MAD): how it is measured was reworded
    • DescriptionVital signs: Body Temperature (SAD): how it is measured was reworded
    • DescriptionVital signs: Heart Rate (MAD): how it is measured was reworded
    • DescriptionVital signs: Heart Rate (SAD): how it is measured was reworded
    • DescriptionVital signs: Systolic and Diastolic Blood Pressure (MAD): how it is measured was reworded
    • DescriptionVital signs: Systolic and Diastolic Blood Pressure (SAD): how it is measured was reworded
    Secondary outcomes 9 edited, 2 description edited
    What changed in the outcomes
    • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC₀AUC0-t) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve ExtrapolatedFrom Time Zero to Infinity (AUCinf) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Time to Maximum Plasma Concentration (Tmax) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Terminal Elimination Half-Life (t1/2) (SAD)Time frame: Day 1 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Area Under the Concentration-Time Curve ExtrapolatedFrom Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
    • EditedPharmacokinetic ParametersParameter: Accumulation Ratio (Rac) (MAD)Time frame: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)
    • DescriptionPharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD): how it is measured was reworded
    • DescriptionPharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD): how it is measured was reworded
    + 5 other changes: verification date, description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07282145
Lead sponsor
Bichedam Co., Ltd.
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Sep 22, 2025
Primary completion
May 15, 2026
Completion
May 15, 2026
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion